Compare ADMA Biologics Inc (ADMA) vs SiTime Corporation (SITM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs SiTime Corporation — how do they compare? ADMA Biologics Inc trades at $9.26 (market cap $2.13B), while SiTime Corporation trades at $609.25 (market cap $17.74B). The key difference: SiTime Corporation is far larger — about 8.3× ADMA Biologics Inc's market cap, and SiTime Corporation is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | SITM | |
|---|---|---|
Market Cap | $2.13B | $17.74B |
Sector | Health | Technology |
52-Week High | $20.38 | $901.60 |
52-Week Low | $7.60 | $190.16 |
Enterprise Value | $2.20B | $16.95B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
SITM trades at $615.46, up 2.29% today, showing strong momentum with three consecutive quarterly earnings beats. The stock faces technical headwinds with a bearish moving average signal, while fundamentals reveal robust revenue growth but negative profitability metrics. Recent news highlights the completed acquisition of Renesas' timing business and strong AI-driven demand, with management raising full-year growth guidance to at least 80%.
The outlook remains promising due to accelerating AI infrastructure demand and strategic acquisitions, though investors face risks from negative profit margins and high valuation multiples. Analyst consensus is unanimously bullish with a $743.75 price target representing 21% upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About SiTime Corporation
SiTime Corporation is a leading provider of MEMS-based silicon timing solutions used in various electronic applications. The company’s products, including oscillators, resonators, and clock ICs, are designed to replace traditional quartz-based timing devices, offering superior performance, reliability, and smaller size in harsh environments. SiTime's solutions are adopted across high-growth markets such as 5G, data centers, industrial IoT, and automotive, positioning the company as a key enabler for next-generation electronic systems.
Read more on SITM →
